BRPI0917350A2 - Oip5 como um gene alvo para terapia e diagnose de câncer - Google Patents

Oip5 como um gene alvo para terapia e diagnose de câncer

Info

Publication number
BRPI0917350A2
BRPI0917350A2 BRPI0917350-1A BRPI0917350A BRPI0917350A2 BR PI0917350 A2 BRPI0917350 A2 BR PI0917350A2 BR PI0917350 A BRPI0917350 A BR PI0917350A BR PI0917350 A2 BRPI0917350 A2 BR PI0917350A2
Authority
BR
Brazil
Prior art keywords
oip5
diagnosis
target gene
cancer therapy
cancer
Prior art date
Application number
BRPI0917350-1A
Other languages
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Akira Togashi
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0917350A2 publication Critical patent/BRPI0917350A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0917350-1A 2008-08-28 2009-08-24 Oip5 como um gene alvo para terapia e diagnose de câncer BRPI0917350A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19053008P 2008-08-28 2008-08-28
PCT/JP2009/004056 WO2010023864A1 (en) 2008-08-28 2009-08-24 Oip5 as a target gene for cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
BRPI0917350A2 true BRPI0917350A2 (pt) 2015-08-11

Family

ID=41721047

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917350-1A BRPI0917350A2 (pt) 2008-08-28 2009-08-24 Oip5 como um gene alvo para terapia e diagnose de câncer

Country Status (9)

Country Link
US (1) US20110160288A1 (pt)
EP (1) EP2352826A1 (pt)
JP (1) JP2012501162A (pt)
KR (1) KR20110063494A (pt)
CN (1) CN102197134A (pt)
BR (1) BRPI0917350A2 (pt)
CA (1) CA2735148A1 (pt)
RU (1) RU2011111411A (pt)
WO (1) WO2010023864A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273144B (zh) 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
AU2014321200A1 (en) * 2013-09-23 2016-05-05 The University Of Chicago Methods and compositions relating to cancer therapy with DNA damaging agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311540T3 (es) * 2000-08-28 2009-02-16 Agensys, Inc. Acido nucleico y proteina correspondiente llamada 85p1b3 util en el tratamiento y deteccion del cancer.
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
JP5109131B2 (ja) * 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
US20070026424A1 (en) * 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
CN101273144B (zh) * 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
EP2295570A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2008069621A1 (en) * 2006-12-08 2008-06-12 Korea Research Institute Of Bioscience And Biotechnology Novel use of mig12 and oip5 genes

Also Published As

Publication number Publication date
EP2352826A1 (en) 2011-08-10
US20110160288A1 (en) 2011-06-30
WO2010023864A1 (en) 2010-03-04
KR20110063494A (ko) 2011-06-10
CN102197134A (zh) 2011-09-21
CA2735148A1 (en) 2010-03-04
JP2012501162A (ja) 2012-01-19
RU2011111411A (ru) 2012-10-10

Similar Documents

Publication Publication Date Title
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
BRPI1014099A2 (pt) alvo bioabsorvível para procedimento de diagnóstico ou terapêutico
PT2829881T (pt) Diagnóstico para cancro colo-rectal
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
EP2340851A4 (en) DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
HUE072183T2 (hu) Génterápia neurodegeneratív betegségekre
BRPI1015215A2 (pt) porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BR112012005594A2 (pt) tratamento de câncer
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BR112013020454A2 (pt) método de diagnóstico de câncer e kit para diagnóstico usando medição de atividade de célula nk
PL2438445T3 (pl) Sposoby diagnozowania raków gruczołu krokowego
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
EP2627333A4 (en) Combination treatment of cancer
PL2456889T3 (pl) Markery diagnostyczne raka błony śluzowej trzonu macicy
IL218118A0 (en) Target genes for cancer therapy
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt) compostos para tratamento de câncer
DE102009038785A8 (de) Longitudinal-Antrieb für Patientenlagerungssysteme
EP2707710A4 (en) CANCER DIAGNOSIS
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
DK2245463T3 (da) Diagnostisk fremgangsmåde
BR112013015481A2 (pt) catalisadores de hidrotratamento sustentados com titânia
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.